Le nouveau site SLL Canada (en français), qui comportera de nombreuseséliorations, est en construction. Par conséquent, vous êtes toujours sur le site précédent. Nous nous excusons de ce délai et travaillons à rendre disponible le nouveau site le plus vite possible.
A community of researchers and honoured heroes for a common cause.
Small molecule targeting of STAT5 protein's SH2 domain
Our group has developed a new molecule, AC-3-19, that shows significant promise in the lab and in animal models of leukemia. It works by binding to STAT5 protein in cancer cells and switching it off. Significantly, healthy cells do not suffer side effects, meaning the molecule has the potential to become a gentler, more targeted chemotherapy drug.
MLL1 is one of the most commonly rearranged genes in human AML and ALL in adults and children, and identifies a patient population with particularly poor prognosis. We recently developed OICR-414, a drug-like small molecule that inhibits the essential WDR5-MLL1 interaction in cells. We will assess OICR-414's effectiveness at disrupting MLL1 function and its effects on leukemic cells in order to explore its potential as a therapeutic agent in leukemia.